These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 30393467)

  • 1. Group sequential crossover trial designs with strong control of the familywise error rate.
    Grayling MJ; Wason JMS; Mander AP
    Seq Anal; 2018; 37(2):174-203. PubMed ID: 30393467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group sequential designs with prospectively planned rules for subpopulation enrichment.
    Rosenblum M; Luber B; Thompson RE; Hanley D
    Stat Med; 2016 Sep; 35(21):3776-91. PubMed ID: 27076411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Tests of Multiple Hypotheses Controlling Type I and II Familywise Error Rates.
    Bartroff J; Song J
    J Stat Plan Inference; 2014 Oct; 153():100-114. PubMed ID: 25092948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimised multi-arm multi-stage clinical trial design for unknown variance.
    Grayling MJ; Wason JMS; Mander AP
    Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination with familywise control of both type I and type II errors in clinical trials.
    Wang B; Ting N
    J Biopharm Stat; 2016; 26(5):951-65. PubMed ID: 26881972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
    Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
    Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and monitoring of multi-arm multi-stage clinical trials.
    Ghosh P; Liu L; Senchaudhuri P; Gao P; Mehta C
    Biometrics; 2017 Dec; 73(4):1289-1299. PubMed ID: 28346823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Aggregated N-of-1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies.
    Blackston JW; Chapple AG; McGree JM; McDonald S; Nikles J
    Healthcare (Basel); 2019 Nov; 7(4):. PubMed ID: 31698799
    [No Abstract]   [Full Text] [Related]  

  • 17. Online error rate control for platform trials.
    Robertson DS; Wason JMS; König F; Posch M; Jaki T
    Stat Med; 2023 Jun; 42(14):2475-2495. PubMed ID: 37005003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of chronic kidney disease trial designs and analysis strategies.
    Lawrence J
    Kidney Res Clin Pract; 2021 Mar; 40(1):62-68. PubMed ID: 33663034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates.
    Bartroff J; Song J
    Scand Stat Theory Appl; 2016 Mar; 31(1):3-19. PubMed ID: 26985125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A note on familywise error rate for a primary and secondary endpoint.
    Proschan MA; Follmann DA
    Biometrics; 2023 Jun; 79(2):1114-1118. PubMed ID: 35355244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.